AACC objects to FDA's at-home virus kit clearance, following go-ahead for Everlywell

By Emily Hayes, LabPulse.com editor in chief

May 21, 2020 -- The American Association for Clinical Chemistry (AACC) has notified the U.S. Food and Drug Administration (FDA) that it objects to the agency's recent emergency use authorization (EUA) of an "unproven" at-home coronavirus collection kit.

The FDA has been approving products related to SARS-CoV-2 rapidly through the EUA pathway. In a letter to FDA Commissioner Stephen Hahn, the AACC said that this haste has resulted in the "introduction of an unproven product into the market." The letter referenced a product that received clearance on May 16, without noting a product or company name.

The FDA granted emergency authorization to Everlywell's at-home nasal sample collection kit for COVID-19 testing on May 15, noting at the time that this is the only product of its kind authorized for use with multiple COVID-19 diagnostic tests.

In the letter to the FDA, President Carmen Wiley, PhD, said there is insufficient information about the quality of the product in the EUA.

"A review of the FDA's EUA to this company does not indicate that adequate clinical studies were performed to validate the kit or that good manufacturing practices were followed to develop it," she wrote. "Further, the company selling the kit is not a laboratory."

Increasing access to home-use collection kits can expand testing capacity and meet the need for fast diagnoses, but inaccurate results can do more harm than good, she wrote, urging the FDA to improve transparency in its regulatory decisions.

"We urge the FDA to withdraw its approval of this EUA or release the underlying clinical information that served as the basis for its expedited review," Wiley wrote. "Authorization for this test kit should not be granted until the FDA has received and assessed the missing information and has released these data to the public."

FDA authorizes home COVID-19 nasal sample kit
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Everlywell's at-home nasal sample collection kit for COVID-19...
AACC provides a steer on antibody testing for novel coronavirus
The American Association for Clinical Chemistry (AACC) is advising that antibody testing for the novel coronavirus should be limited to diagnostics that...
FDA policy change may put an end to 'Wild West' of coronavirus antibody tests
The U.S. Food and Drug Administration (FDA) is cracking down on requirements for commercial manufacturers of antibody tests for the novel coronavirus,...
AACC warns coronavirus self-tests vulnerable to flawed specimen collection
The American Association for Clinical Chemistry (AACC) has recommended that the U.S. Food and Drug Administration issue a warning about COVID-19 at-home...
U.S. reopening plans shine light on testing supply shortages
Plans to reopen U.S. state economies in a phased fashion have raised concerns about a lack of capacity for novel coronavirus testing due to a shortage...

Copyright © 2020 LabPulse.com

Last Updated np 5/21/2020 4:53:20 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current